A double arm, prospective and exploratory phase II clinical study of Camrelizumab combined with or without bevacizumab / apatinib mesylate in the treatment of locally advanced rectal cancer

ABSTRACT: Interventions: control group:Camrelizumab;experimental group 1:Camrelizumab;experimental group:bevacizumab / apatinib Primary outcome(s): complete pathological response rate Study Design: Non randomized control

DISEASE(S): Colorectal Cancer

PROVIDER: 2759992 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR